FIND2CURE
FIND2CURE
We believe that the more we know about diseases molecular underpinnings, the faster we can transform early diagnosis, prevention and treatment options for patients.
Find2Cure (F2C) Health & Social was founded by a core of team members from various related fields, Biomedical Scientist, Clinician’s, and Computer data scientists that experienced first-hand and linked to a social cause in bringing and creating precision and personalized treatment plans for patients suffering from various disorders Cancer, Diabetes, Cardiovascular, Neurological and Infectious Diseases. F2C is a unique kind of Genome -Drug Match Sequencing company - it’s our mission that will sets us apart. Our Goal is to Accelerate the Impact of Precision Medicine for Cancer Patients.
With growing data availability, yet its heterogeneity and complexity. To go from patterns to insights, people –That’s why our founding team united behind the vision to simplify latest available healthcare informatics data and related pipelines in using high end Omincs-In-Silico, approaches in building a stronger data sets for developing Gene-Drug match systems in curing various metabolic disorders in giving early diagnosis, prevention, treatment and related health-care solutions for life threating disorders in find2cure (F2C) that helps more people live longer, happier and healthier lives. We won’t rest until each patient has been treated with their best possible precision and personalized therapy.
We use a cutting edge accuracy big data pipeline medical technology to characterize novel, biomarker early signs of the particular disorders and give them a treatment plan by using affirmed precision and personalized medical treatments plans. We consolidate progressed testing, genuine information, and an enormous scope of clinical available preliminary data to distinguish and convey ideal therapies for patients with different chronic inflammations (Arteriosclerosis, Autoimmune disorder, Cancer, Diabetes, Microbial infections and Neurological diseases). The Preliminary patient beginning phase disease study to assess the clinical advantage of customized repeat observing and biomarker-guided and early treatment plans using precise gene to drug match evolving technologies. We are a nascent Diagnostic Research and Developing company applying for the various investor, government and small industrial in-house grants to development facility to achieve the vision and mission of Find2Cure (F2C).
We @ F2C imagine a future where each understanding each disease condition gets their most ideal precise treatment plans. Along with our accomplices, we are introducing a future where the relationship of patients profiles and treatments is completely streamlined, creating unrivaled patient results and quicker medication endorsements. F2C NGS and Molecular profiling is an extensive genomic profiling test that includes the least sample necessities in the business so more patients can get the outcomes and medicines what they need in a quicker fashion.
We give an arrangement of convincing clinical preliminaries close by our test outcomes so that if a patient's best treatment is investigational, they can get to it. Nearby accessibility of these preliminary data guarantees that patients approach greater treatment alternatives options in-person using Precision and Personalized medicine concepts.
We are improving patients' lives with nonstop advancement. We are making a learning circle that produces and applies information to control bits of knowledge advising new treatment experiences and the revelation of novel biomarkers. Our group of clinicians, researchers, and scientist constantly gains from the furthest down the line clinical-spec information to devise better biomarker-guided treatment plans. We at that point cooperate with biopharma to get those treatment plans to patients.
Personalized Medicine and Acceleration
Early Detections, Prevention and Management
Participate in Private & Govt Grants
FIND2CURE
